Deepak L. Bhatt MD, MPH, FACC, FAHA, FESC, MSCAI
Icahn School of Medicine at Mount Sinai in New York City
Deepak L. Bhatt MD, MPH, FACC, FAHA, FESC, MSCAI, is the Director of the Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai in New York City.
After graduating as valedictorian from Boston Latin School, Dr. Bhatt obtained his science degree as a National Merit Scholar at MIT. He received his MD from Cornell and MPH from Harvard. He is working on his Executive MBA from Oxford. He trained in internal medicine at the University of Pennsylvania and in cardiology at Cleveland Clinic. He completed fellowships in interventional cardiology and cerebral and peripheral vascular intervention and served as Chief Interventional Fellow at Cleveland Clinic, where he spent many years as an interventional cardiologist, Associate Professor of Medicine, Director of the Interventional Cardiology Fellowship, Associate Director of the Cardiovascular Medicine Fellowship, and Associate Director of the Cardiovascular Coordinating Center. He then served as the Chief of Cardiology at VA Boston Healthcare System and subsequently as Executive Director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital. He was a Senior Investigator in the TIMI Study Group and Editor-in-Chief of the Harvard Heart Letter. He became a full Professor of Medicine at Harvard Medical School in 2012. He was selected by Brigham and Women’s Hospital as the 2014 Eugene Braunwald Scholar. He received the Research Mentor Award from Brigham and Women’s Hospital Department of Medicine in 2016, the Eugene Braunwald Teaching Award for Excellence in the Teaching of Clinical Cardiology from Brigham and Women’s in 2017, ACC’s Distinguished Mentor Award in 2018, AHA’s Distinguished Scientist Award in 2019, NLA’s Honorary Lifetime Membership Award in 2021, and SCAI’s Master designation in 2022.
Dr. Bhatt has authored or co-authored over 2000 publications and has been listed by the Web of Science Group as a Highly Cited Researcher from 2014 to 2023. He is the Editor of Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease and of Opie's Cardiovascular Drugs: A Companion to Braunwald's Heart Disease. He is one of the co-Editors of Braunwald’s Heart Disease. He had served as Senior Associate Editor for News and Clinical Trials for ACC.org and is the Editor of the Journal of Invasive Cardiology. He was the PI for CHARISMA, CRESCENDO, COGENT, REDUCE-IT, SOLOIST, SCORED, and ENTRIGUE and co-PI of the three CHAMPION trials, STAMPEDE, SAVOR-TIMI 53, SYMPLICITY HTN-3, THEMIS, THEMIS-PCI, and the REACH registry. In 2014, he was listed in the AHA/ASA top advances in heart disease and stroke research (for STAMPEDE and SYMPLICITY HTN-3); in 2018, REDUCE-IT was listed and also named the top cardiology trial by NEJM; in 2020 and again in 2021, SOLOIST and SCORED were listed by the AHA. He was the inaugural Chair of the AHA-GWTG Quality Oversight Committee and served as a Trustee of the ACC, and currently serves on the Board of Directors of the AHA New York City chapter.
Dr. Jennifer Green
Dr. Jennifer Green is a professor of medicine in the division of endocrinology, metabolism, and nutrition at Duke University and a faculty member of the Duke Clinical Research Institute. Her research has focused upon strategies to treat diabetes mellitus and reduce the risk of cardiovascular, kidney and other diabetes-related complications. Her work with the DCRI has included protocol development, oversight of adjudication committees, and clinical and operational leadership for several large, international trials designed to determine the cardiovascular effects of glucose-lowering medications (TECOS, EXSCEL, and Harmony Outcomes). She currently serves as US coordinating center PI and US national representative for the EMPA-Kidney trial of empagliflozin therapy in patients with chronic kidney disease. Dr. Green has concluded three years of service as a member of the American Diabetes Association’s (ADA) Professional Practice Committee, which publishes the organization’s annual Standards of Care in Diabetes. She is now a member of the ADA-EASD writing group which recently revised a joint consensus statement on the management of hyperglycemia in type 2 diabetes.
Joshua A. Beckman, MD, MSc
Dr. Joshua Beckman is a Professor of Medicine and Director of Vascular Medicine at
University of Texas Southwestern, both in Dallas, Texas. After earning his medical degree
from New York University School of Medicine in New York City, he completed an
internship, residency, and chief residency in internal medicine at Columbia Presbyterian
Medical Center and postgraduate fellowships in cardiovascular medicine and vascular
medicine at Brigham and Women's Hospital. Dr. Beckman served as the Cardiovascular
Fellowship Program Director for 7 years at Brigham and Women’s Hospital. He is board
certified in Cardiovascular Disease.
Dr. Beckman is the Director of Vascular Medicine within the Department of Medicine at
UTSW. He cares for patients with a wide range of both heart and vascular disorders. Dr.
Beckman has a special interest in peripheral artery disease, venous thromboembolism,
aortic disease, perioperative management, thermal (temperature-related) diseases, and
vasculitis.
Dr. Beckman is active in professional societies and has served in leadership roles for the
major cardiovascular organizations. He is a former President of the Society for Vascular
Medicine and is a past Chair of the American Heart Association’s Peripheral Vascular
Disease Council. He has participated in multiple guidelines writing committees on
Perioperative Risk Assessment and Management, Peripheral Artery Disease, and Thoracic
Aortic Disease. He currently serves as the Chair for the AHA/ACC Joint Committee on
Guidelines, is the Chair of the AHA Vascular Health and Advisory Committee, is the
President of VIVA, and is an Associate Editor for the journal Circulation, the premier peer-
reviewed cardiovascular journal. Dr. Beckman is a well-known educator, having won the
Eugene Braunwald teaching award at Brigham and Women’s Hospital and the W. Procter
Harvey Young Teacher Award from the American College of Cardiology.
Dr. Beckman's research focuses on the mechanisms that cause vascular dysfunction,
susceptibility to atherosclerosis, and functional limitations in peripheral artery disease,
translating discoveries made at the lab bench to human beings. Dr. Beckman has an
ongoing interest in understanding how diabetes impairs vascular function, the vascular
and skeletal muscle mechanisms of limb dysfunction in PAD, the mechanisms of
revascularization failure, and the mechanisms by which GLP-1 affects endothelial cell
signaling and vasomotor function. He has mentored trainees at all levels from medical
students to junior faculty.
Dr Matthew Lee
Dr Matthew Lee trained in medicine at the University of Edinburgh (MBChB 2010). He undertook general professional training in medicine in South East Scotland (2010-2012) and the West of Scotland (2012-2014). He is a Cardiology Specialist Registrar in the West of Scotland (from 2014) and Clinical Lecturer at the School of Cardiovascular and Metabolic Health at the University of Glasgow. His interests include diabetes, pharmacotherapy (SGLT2i, GLP-1RA, myosin inhibitors), heart failure, cardiomyopathies, obesity/weight loss, clinical trials, meta-analysis, systematic review and multi-modality imaging (CMR, renal MRI, TTE, lung ultrasound). He was awarded the Bellahouston Medal for his PhD at the University of Glasgow (2022), based on the SUGAR-DM-HF trial. He is currently a CardioVascular Clinical Trialists (CVCT) Future Trialists Fellow. He serves on trial steering committees (SEQUOIA-HCM) and clinical event committees (FINEARTS-HF, REVIVED-BCIS2, CABG-ACS). He is a co-grant holder for BIOPEF, EMPRESS-MI, DAPA-RESIST and SUGAR-DM-HF. He is/was a co-/sub-investigator for STEP-HFpEF, SOUL, Dapa-HF, PARADISE-MI, PARAGON-HF, IRONMAN, FAMOUS-NSTEMI, CABG-ACS and the Air Pollution Facemask Study.
Vanita R. Aroda, MD
Vanita Aroda is the Director of Diabetes Clinical Research at the Brigham and Women's Hospital in Boston, MA, and is an Associate Professor of Medicine at Harvard Medical School. Dr. Aroda completed her training in Internal Medicine and in Endocrinology, Diabetes and Metabolism at the University of California San Diego, CA, USA.
Dr. Aroda has an interest and published record in diabetes prevention and novel therapeutics in diabetes and weight management. She also has a strong interest in understanding therapeutic interventions in large multicenter clinical trials and their applicability and integration into care. Dr. Aroda has years of experience in clinical trial conduct and leadership, has served as an investigator on the National Institutes of Health-funded GRADE, D2d, and DPPOS studies, and as the national or international signatory Principal Investigator for multiple therapeutic clinical trials. Dr. Aroda served on the Professional Practice Committee of the American Diabetes Association (Standards of Care in Diabetes 2021, 2022, 2023) and on the international 2022 ADA-EASD Consensus Group for the Management of Hyperglycemia in Type 2 Diabetes.
